Cybin (NYSE:CYBN – Get Free Report) is one of 444 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Cybin to similar businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.
Volatility & Risk
Cybin has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Cybin’s peers have a beta of 1.26, indicating that their average share price is 26% more volatile than the S&P 500.
Profitability
This table compares Cybin and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cybin | N/A | -109.05% | -97.85% |
Cybin Competitors | -8,581.07% | -107.97% | -23.29% |
Valuation & Earnings
Gross Revenue | Net Income | Price/Earnings Ratio | |
Cybin | N/A | -$35.93 million | -44.15 |
Cybin Competitors | $148.01 million | -$13.29 million | 148.87 |
Cybin’s peers have higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
17.9% of Cybin shares are held by institutional investors. Comparatively, 29.6% of shares of all “Biotechnology” companies are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 25.7% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Cybin and its peers, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cybin | 0 | 0 | 3 | 0 | 3.00 |
Cybin Competitors | 735 | 2180 | 5106 | 56 | 2.56 |
Cybin currently has a consensus price target of $50.50, indicating a potential upside of 471.91%. As a group, “Biotechnology” companies have a potential upside of 10.68%. Given Cybin’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than its peers.
Summary
Cybin peers beat Cybin on 9 of the 13 factors compared.
About Cybin
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.